Citius Pharmaceuticals, Inc.CTXR
時価総額
$1070.2万
PER
がん治療薬や感染症治療薬の開発の新興企業。LYMPHIRやMino‑Lokを展開。2023年10月の合併、2024年11月25日の1-for-25逆株式分割、11月18日の480,000株発行で300万ドル調達。米国中心の展開。
| 2011年 9月30日 | 2012年 9月30日 | 2013年 9月30日 | 2015年 9月30日 | 2016年 9月30日 | 2017年 9月30日 | 2018年 9月30日 | 2019年 9月30日 | 2020年 9月30日 | 2021年 9月30日 | 2022年 9月30日 | 2023年 9月30日 | 2024年 9月30日 | |
| Net Loss | - | - | - | - | - | - | - | - | - | - | - | - | -39,425,839 |
| Stock-based compensation – general and administrative | - | - | - | 486,271 | 732,151 | 986,620 | 779,701 | 715,983 | 803,261 | 1 | 4 | 7 | 12 |
| Issuance of common stock for services | - | - | - | - | - | - | - | - | - | - | - | 102,000 | 284,176 |
| Amortization of operating lease right-of-use asset | - | - | - | - | - | - | - | - | - | - | 176,754 | 191,648 | 208,179 |
| Depreciation | - | - | - | - | 1,343 | 2,632 | 1,753 | 893 | 844 | 1,492 | 2,923 | 2,668 | 1,432 |
| Deferred income tax expense | - | - | - | - | - | - | - | - | - | - | 576,000 | 576,000 | 576,000 |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 2 |
| Prepaid expenses | - | - | - | -60,000 | -40,759 | -572,098 | -162,514 | -9,621 | 74,126 | 3 | 111,176 | 5 | 945,389 |
| Accounts payable | 906 | - | 11,474 | 452,981 | 105,230 | -306,725 | 971,013 | 1 | -857,307 | -579,140 | -111,717 | 2 | 2 |
| Accrued expenses | 3,950 | 4,150 | 2,700 | -52,057 | 351,182 | -397,183 | 70,739 | 64,568 | -82,185 | 457,920 | 783,434 | -929,094 | -459,273 |
| Accrued compensation | - | - | - | - | - | - | - | - | - | - | - | - | 72,035 |
| Operating lease liability | - | - | - | - | - | - | - | - | -123,254 | -158,999 | -177,237 | -196,989 | -218,380 |
| Net Cash Used In Operating Activities | -20,781 | -20,324 | -20,604 | -2,385,416 | -5,900,421 | -7,971,205 | -11,318,138 | -12,437,751 | -16,930,658 | -24,250,414 | -28,361,256 | -29,060,212 | -28,201,375 |
| License payment | - | - | - | - | - | - | - | - | - | - | - | - | 5 |
| Net Cash Used In Investing Activities | - | - | - | - | 255,748 | -2,126 | - | - | -1,831 | -40,006,938 | - | - | -5,000,000 |
| Proceeds from common stock option exercises | - | - | - | - | - | 40 | - | - | - | - | - | 31,267 | - |
| Merger, net | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
| Net proceeds from registered direct offerings | - | - | - | - | - | 6 | - | - | - | 71 | - | 14 | 14 |
| Net Cash Provided By Financing Activities | 36,493 | 56,740 | 77,209 | 2 | 5 | 11 | 17 | 11 | 23 | 120 | - | 14 | 10 |
| Net Change in Cash and Cash Equivalents | - | - | - | - | - | - | - | - | 6 | 56 | -28,361,256 | -15,230,762 | -23,229,048 |
| IPR&D Milestones included in License Payable | - | - | - | - | - | - | - | - | - | - | - | - | 28 |
| Prepaid Manufacturing transferred to Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 6 |